Abstract: Provided is a method for correcting a lithography pattern of a surface plasma, including: forming a plurality of test patterns on a test mask; exposing a photoresist layer by using the test mask containing the test patterns to form a plurality of photoresist patterns; establishing a first data table based on a correspondence between the first test parameter and the second test parameter of the test pattern and the first exposure parameter and the second exposure parameter of the photoresist pattern; processing the first data table according to the first exposure parameter to obtain a second data table; and respectively correcting second test parameters of a plurality of design patterns according to the second data table to obtain corrected design patterns, and manufacturing a mask for exposure by using the corrected design patterns.

Abstract: The present invention relates to in vivo and in vitro methods, agents and compound screening assays for inducing anabolic stimulation of chondrocytes, including cartilage formation enhancing pharmaceutical compositions, and the use thereof in treating and/or preventing a disease involving a systemic or local decrease in mean cartilage thickness in a subject.

Abstract: The present invention relates to in vivo and in vitro methods, agents and compound screening assays for inducing anabolic stimulation of chondrocytes, including cartilage formation enhancing pharmaceutical compositions, and the use thereof in treating and/or preventing a disease involving a systemic or local decrease in mean cartilage thickness in a subject.

Abstract: The present invention relates to in vivo and in vitro methods, agents and compound screening assays for inducing anabolic stimulation of chondrocytes, including cartilage formation enhancing pharmaceutical compositions, and the use thereof in treating and/or preventing a disease involving a systemic or local decrease in mean cartilage thickness in a subject.

Abstract: The present invention relates to in vivo and in vitro methods, agents and compound screening assays for inducing anabolic stimulation of chondrocytes, including cartilage formation enhancing pharmaceutical compositions, and the use thereof in treating and/or preventing a disease involving a systemic or local decrease in mean cartilage thickness in a subject.

Abstract: The present invention relates to methods of introducing an expressible non-viral nucleic acid sequence into a T lymphocyte cell, a B-cell, or a mast cell, comprising contacting the cell with a viral particle containing a modified viral coat proteins containing adenoviral amino acid sequence from an adenoviral serotype Ad35 or Ad51 fiber protein, arrays of subpopulations of cells made by such methods, and a method for a ex vivo transduction of a population of cells.

Abstract: The present invention relates to in vivo and in vitro methods, agents and compound screening assays for inducing anabolic stimulation of chondrocytes, including cartilage formation enhancing pharmaceutical compositions, and the use thereof in treating and/or preventing a disease involving a systemic or local decrease in mean cartilage thickness in a subject.

Abstract: The present invention relates to a method of introducing an expressible non-viral nucleic acid sequence into a cell having a common non-universal binding receptor and selected from T lymphocytes, B-, and mast cells, comprising contacting said cell with a viral vector comprising a recombinant nucleic acid sequence containing sequence for said expressible non-viral nucleic acid and comprising a modified viral coat consisting of native viral coat proteins and modified coat protein containing adenoviral amino acid sequence from an adenoviral serotype 35 or 51 fibre protein, wherein said adenoviral sequence of said modified protein is a ligand for said binding receptor. Alternatively said vector comprises a sequence coding for a viral capsid consisting of native adenoviral capsid proteins and modified capsid protein containing amino acid sequence from an adenoviral serotype other than the serotype of said native capsid proteins, wherein said modified protein is a ligand for said binding receptor.